- Home
- BKYI vs CHRO Comparison
BKYI vs CHRO Comparison
Compare BKYI & CHRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BKYI
- CHRO
- Stock Information
- Founded
- BKYI 1993
- CHRO 2002
- Country
- BKYI United States
- CHRO United States
- Employees
- BKYI N/A
- CHRO N/A
- Industry
- BKYI Computer Software: Prepackaged Software
- CHRO
- Sector
- BKYI Technology
- CHRO
- Exchange
- BKYI Nasdaq
- CHRO Nasdaq
- Market Cap
- BKYI 3.2M
- CHRO 3.9M
- IPO Year
- BKYI 1997
- CHRO 2024
- Fundamental
- Price
- BKYI $0.94
- CHRO $0.66
- Analyst Decision
- BKYI
- CHRO Strong Buy
- Analyst Count
- BKYI 0
- CHRO 1
- Target Price
- BKYI N/A
- CHRO N/A
- AVG Volume (30 Days)
- BKYI 6.3M
- CHRO 100.6K
- Earning Date
- BKYI 11-14-2024
- CHRO 11-13-2024
- Dividend Yield
- BKYI N/A
- CHRO N/A
- EPS Growth
- BKYI N/A
- CHRO N/A
- EPS
- BKYI N/A
- CHRO N/A
- Revenue
- BKYI $7,292,394.00
- CHRO N/A
- Revenue This Year
- BKYI N/A
- CHRO N/A
- Revenue Next Year
- BKYI $24.64
- CHRO N/A
- P/E Ratio
- BKYI N/A
- CHRO N/A
- Revenue Growth
- BKYI N/A
- CHRO N/A
- 52 Week Low
- BKYI $0.52
- CHRO $0.52
- 52 Week High
- BKYI $4.50
- CHRO $6.00
- Technical
- Relative Strength Index (RSI)
- BKYI 45.22
- CHRO 48.22
- Support Level
- BKYI $1.13
- CHRO $0.63
- Resistance Level
- BKYI $1.31
- CHRO $0.69
- Average True Range (ATR)
- BKYI 0.17
- CHRO 0.06
- MACD
- BKYI -0.01
- CHRO 0.01
- Stochastic Oscillator
- BKYI 1.93
- CHRO 52.55
About BKYI BIO-key International Inc.
BIO-key International Inc is a fingerprint biometric technology company. It develops and markets fingerprint biometric identification and identity verification technologies, as well as related identity management and credentialing hardware and software solutions. Its product portfolio comprises SideSwipe, SidePass, EcoID, WEB-key, and others. The company generates its revenue in the form of Services, License fees, and others.
About CHRO Chromocell Therapeutics Corporation
Chromocell Therapeutics Corp is a clinical-stage biotechnology company focused on developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain and other associated medical conditions. The company's initial clinical focus is to selectively target the sodium ion-channel known as NaV1.7 for the treatment of various types of chronic neuropathic pain and eye pain. The Company's portfolio also includes pre-clinical work on other sodium channel receptor subtypes, and the company intends to explore these and other compounds for the treatment of additional pain indications.